AI assistant
Sending…
FARON PHARMACEUTICALS OY — Major Shareholding Notification 2017
Mar 3, 2017
7635_rns_2017-03-03_452ef15c-7b2e-4170-a9bc-0fd7359be0cc.html
Major Shareholding Notification
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 4778Y
Faron Pharmaceuticals Oy
03 March 2017
| TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi | ||||
| 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii |
Faron Pharmaceuticals Oy | |||
| 2 Reason for the notification (please tick the appropriate box or boxes): | ||||
| An acquisition or disposal of voting rights | Yes | |||
| An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | ||||
| An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | ||||
| An event changing the breakdown of voting rights | ||||
| Other (please specify): | ||||
| 3. Full name of person(s) subject to the notification obligation: iii |
City Financial Investment Company Limited, acting as Investment Manager and Authorised Corporate Director of the City Financial Absolute Equity Fund | |||
| 4. Full name of shareholder(s) (if different from 3.):iv | BNY Mellon Trust and Depositary as Trustee to the City Financial Absolute Equity Fund | |||
| 5. Date of the transaction and date on which the threshold is crossed or reached: v |
2.3.2017 | |||
| 6. Date on which issuer notified: | 2.3.2017 | |||
| 7. Threshold(s) that is/are crossed or reached: vi, vii |
4%,5% | |||
| 8. Notified details: | ||||||||||||||||
| A: Voting rights attached to shares viii, ix | ||||||||||||||||
| Class/type of shares if possible using the ISIN CODE |
Situation previous to the triggering transaction |
Resulting situation after the triggering transaction | ||||||||||||||
| Number of Shares |
Number of Voting Rights |
Number of shares |
Number of voting rights |
% of voting rights x | ||||||||||||
| Direct | Direct xi | Indirect xii | Direct | Indirect | ||||||||||||
| FI4000153309 | 1,000,000 | 1,000,000 | 1,429,000 | 1,429,000 | 0 | 5.15% | 0 | |||||||||
| B: Qualifying Financial Instruments | ||||||||||||||||
| Resulting situation after the triggering transaction | ||||||||||||||||
| Type of financial instrument |
Expiration date xiii |
Exercise/ Conversion Period xiv |
Number of voting rights that may be acquired if the instrument is exercised/ converted. |
% of voting rights |
||||||||||||
| C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi | ||||||||||||||||
| Resulting situation after the triggering transaction | ||||||||||||||||
| Type of financial instrument |
Exercise price | Expiration date xvii | Exercise/ Conversion period xviii |
Number of voting rights instrument refers to | % of voting rights xix, xx | |||||||||||
| Nominal | Delta | |||||||||||||||
| Total (A+B+C) | ||||||||||||||||
| Number of voting rights | Percentage of voting rights | |||||||||||||||
| 1,429,000 | 5.15% | |||||||||||||||
| 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi |
||
| The voting rights are managed and controlled by City Financial Investment Company Limited, Investment manager and ACD to the City Financial Absolute Equity Fund. | ||
| Proxy Voting: | ||
| 10. Name of the proxy holder: | ||
| 11. Number of voting rights proxy holder will cease to hold: |
||
| 12. Date on which proxy holder will cease to hold voting rights: |
||
| 13. Additional information: | ||
| 14. Contact name: | Chris Sturdee | |
| 15. Contact telephone number: | 0207 451 9600 | |
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLGMGGFMFGGNZM
More from FARON PHARMACEUTICALS OY
Major Shareholding Notification
2026
May 18
Regulatory Filings
2026
May 13
Capital/Financing Update
2026
May 6
Major Shareholding Notification
2026
May 5
Board/Management Information
2026
May 5
AGM Information
2026
May 4
Capital/Financing Update
2026
Apr 30
Major Shareholding Notification
2026
Apr 22
Major Shareholding Notification
2026
Apr 20
Major Shareholding Notification
2026
Apr 20